开发中的新型口服抗凝药

New Developing Oral Anticoagulant Medicines

血管内血栓的形成是心肌梗死、不稳定心绞痛及肺栓塞等疾病发生的关键性因素,抗凝药则是目前主要的治疗手段之一。新型口服抗凝药有着疗效显著、使用方便、出血不良反应少等优点,该类药物的研发近年来受到了广泛的关注。研发中的新型口服抗凝药大多数为Xa因子抑制剂(Eribaxaban、LY517717、Darexaban、Letaxaban和DX-9065a等)、直接凝血酶抑制剂AZD0837和IXa因子抑制剂TTP889。本文就目前处于临床开发阶段的新型口服抗凝剂,从其结构、临床研究状态及作用特点等方面进行简要综述,以期为我国新型口服抗凝药的研发与上市前研究提供参考。

The formation of thrombi in intravascular is a key factor in the occurrence of diseases such as myocardial infarction, unstable angina, and pulmonary embolism which usually be treated with anticoagulant medicines. The new oral anticoagulants which will be researched in this passage are more effective and convenient than traditional anticoagulants. Additionally, they have less bleeding and adverse reactions. Most of such developing medicines are belong to Xa factor inhibitors（which include eribaxaban, LY517717, darexaban, letaxaban, DX-9065 a, etc）, direct thrombin inhibitors known as AZD0837, or IXa Factor Inhibitor TTP889. This passage will provide summary of the structural, clinical research state, characteristic of effect, and son on about such developing oral anticoagulants, which will be a reference for developing and researching of new oral anticoagulants.